Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;9(6):737-740.
doi: 10.15252/emmm.201707573.

Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products

Alessandro Aiuti  1   2 , Maria Grazia Roncarolo  1   2 , Luigi Naldini  1   2
Affiliations

Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products

Alessandro Aiuti et al. EMBO Mol Med. 2017 Jun.

Abstract

Gene and cell therapy research recently reached a fundamental milestone toward the goal to deliver new medicines for orphan diseases. In 2016, the European Commission granted market approval to GlaxoSmithKline (GSK) for ex vivo hematopoietic stem cell (HSC) gene therapy for the treatment of adenosine deaminase (ADA)‐deficient severe combined immunodeficiency (SCID), a very rare congenital disorder of the immune system. The new medicine, named Strimvelis™, is an advanced therapy medicinal product (ATMP) (Salmikangas et al, 2015) originally developed by the San Raffaele Telethon Institute for Gene Therapy (SR‐Tiget), a joint venture between Telethon Foundation and San Raffaele Scientific Institute. This ATMP is the first ex vivo stem cell gene therapy to receive regulatory approval anywhere in the world. Strimvelis™ consists of a single infusion of autologous gene‐corrected HSC and is prepared from the patient's own bone marrow (BM) HSCs, which are genetically modified using a gamma‐retroviral vector to insert a functional copy of the ADA gene.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Schematic representation of the key scientific and regulatory milestones in the clinical development of ADA‐SCID gene therapy, leading to its approval in the EU
See this image and copyright information in PMC

References

    1. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F et al (2002) Correction of ADA‐SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410–2413 - PubMed
    1. Aiuti A, Cassani B, Andolfi G, Mirolo M, Biasco L, Recchia A, Urbinati F, Valacca C, Scaramuzza S, Aker M et al (2007) Multilineage hematopoietic reconstitution without clonal selection in ADA‐SCID patients treated with stem cell gene therapy. J Clin Invest 117: 2233–2240 - PMC - PubMed
    1. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I et al (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360: 447–458 - PubMed
    1. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P et al (1995) T lymphocyte‐directed gene therapy for ADA‐ SCID: initial trial results after 4 years. Science 270: 475–480 - PubMed
    1. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, Mazzolari E, Maggioni D, Rossi C, Servida P et al (1995) Gene therapy in peripheral blood lymphocytes and bone marrow for ADA‐ immunodeficient patients. Science 270: 470–475 - PubMed

MeSH terms

Supplementary concepts